ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are...

NOVEL LIVER-TARGETING AGENTS AND THEIR SYNTHESIS
This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with ...

CRYSTALLIZATION OF 4'-EPIDAUNORUBICIN X HCI
The present invention relates to a form of crystalline 4'-epidaunorubicin hydrochloride which is stable and readily soluble, and to a process for the production thereof. This process comprises crystallizing 4'-epidaunorubicin hydrochlori...

CARBOHYDRATE-MEDIATED TUMOR TARGETING
Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein RA and RB are as defined herein. Tumors can be imaged or targeted for therapeutic treatment...

METHOD FOR PRODUCING GLUCOSYLCERAMIDE-CONTAINING MATERIAL
Disclosed is a method for easily and economically producing a highly pure glucosylceramide-containing material in a large amount from a plant material. A highly pure glucosylceramide can be obtained in a large amount by a method for prod...

INHIBITORS OF MICROBIAL INFECTIONS
The present invention finds application in the field of medicine and, in particular, it relates to new compounds for the treatment and/or prevention of HIV; Ebola, Dengue, Hepatitis C, SARS or tuberculosis infections.

WO/2010/149326A1

ACID-LABILE TRIGGER UNITS
The present invention relates to a compound comprising an imine bond as an acid- labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceut...

WO/2010/139692A3

ANTIVIRAL TRITERPENE DERIVATIVES
The present invention encompasses novel triterpene compounds of general Formula (I) wherein RN1, RN2, R11a, R11b, R4, R17, R19 and R20 are defined as in claim 1, which exhibit an antiviral effect and are therefore suitable for the treatm...

WO/2010/139692A2

ANTIVIRAL TRITERPENE DERIVATIVES
The present invention encompasses novel triterpene compounds of general Formula (I) wherein RN1, RN2, R11a, R11b, R4, R17, R19 and R20 are defined as in claim 1, which exhibit an antiviral effect and are therefore suitable for the treatm...

ANTIBACTERIAL DERIVATIVES OF DIBEKACIN
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herei...

ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined here...

AMINOGLYCOSIDE DOSING REGIMENS
The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.

WO/2010/132759A1

ANTIBACTERIAL DERIVATIVES OF DIBEKACIN
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herei...

WO/2010/132839A9

AMINOGLYCOSIDE DOSING REGIMENS
The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.

WO/2010/132760A9

ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined here...

AMINOGLYCOSIDE DOSING REGIMENS
The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.

WO/2010/126435A1

NOVEL GALACTOSIDE INHIBITORS OF GALECTINS
The present invention relates to novel compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding...

SYNTHESIS OF 2 ' -O-FUCOSYLLACTOSE
The present invention relates to an improved synthesis of a trisaccharide of the formula, novel intermediates used in the synthesis and the preparation of the intermediates.

WO/2010/115934A1

SYNTHESIS OF 2'-O-FUCOSYLLACTOSE
The present invention relates to an improved synthesis of a trisaccharide of the formula (1), novel intermediates used in the synthesis and the preparation of the intermediates.

AGENT FOR INHIBITING THICKENING OF PERITONEAL MEMBRANE
Disclosed are: a thickening-inhibiting agent for inhibiting thickening of the peritoneal membrane by which thickening of the peritoneal membrane can be inhibited, prevented or treated with relieved side effects; and a dialysis solution w...

CONJUGATED ANTIMICROBIAL AGENTS
Provided herein are antimicrobial conjugates of two antibiotic agents, exhibiting improved activity also against resistant bacteria, compared to each of the agents separately or their mixture, and having substantially no resistance emerg...